Table 3 Simulated lumefantrine pharmacokinetics parameters in HIV-malaria co-infected patients treated with AL (9960 simulations)
Parameters | Control-arm | Nevirapine-arm | Efavirenz-arm | |||
|---|---|---|---|---|---|---|
Dose | 480 mg bid 3 days | 480 mg bid 3 days | 480 mg bid 3 days | 480 mg bid 5 days | 480 mg bid 7 days | 1200 mg bid 3 days |
Cmax (ng/ml) | 8192.7 (5664.3 - 11896.8) | 10229 (7173.4 - 14606) | 3182.2 (2198.4 - 4586.1) | 3678.2 (2609.7 - 5150.7) | 3887.5 (2690.4 - 5531.4) | 7955 (5496.2 - 11464) |
AUC0-inf (ng.hr/ml) | 784830 (547405–1116250) | 977645 (688477–1383975) | 303130 (211080–431962) | 513760 (359212.5 - 713715) | 755090 (528277–1086525) | 757835 (527702–1079925) |
Tmax (hr) | 66.1 (63.6 - 67.7 ) | 66.1 (60.0 - 67.7 ) | 66.1 (60.4 - 67.6) | - | - | - |
Simulated day 7 plasma concentration (ng/ml) | 858.7 (562.3 - 1333.8) | 1090.3 (704.4 - 1680.4) | 335.5 (215.8 - 519.5) | 1039.4 (678.1- 1552.8) | 1079.2 (694.1- 1689.6) | 838.9 (539.6 - 1298.9) |
Observed day 7 plasma concentration (ng/ml) | 970 (562.1 - 1729) | 1125 (638.8 - 1913) | 300.4 (220.8 - 343.1) | - | - | - |